NR4A1 and breast carcinoma: Even though SLC38A3 exhibits functional features that are almost identical with those of SLC38A5 [7], the expression of the former is actually decreased in breast cancer, and the decrease is independent of the hormone receptor status of the tumor (TCGA database).